Arndt Vogel
Ontario Institute for Cancer Research(CA)University Health Network(CA)University of Toronto(CA)Federal Institute for Risk Assessment(DE)Toronto General Hospital(CA)Princess Margaret Cancer Centre(CA)Medizinische Hochschule Hannover(DE)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Cholangiocarcinoma and Gallbladder Cancer Studies, Pancreatic and Hepatic Oncology Research, Liver Disease Diagnosis and Treatment, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial(2018)5,305 cited
- → Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial(2018)2,498 cited
- → Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study(2020)1,533 cited
- → Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(2022)1,260 cited
- → NASH limits anti-tumour surveillance in immunotherapy-treated HCC(2021)1,187 cited
- → Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(2018)1,047 cited